DE2366609C2 - - Google Patents
Info
- Publication number
- DE2366609C2 DE2366609C2 DE2366609A DE2366609A DE2366609C2 DE 2366609 C2 DE2366609 C2 DE 2366609C2 DE 2366609 A DE2366609 A DE 2366609A DE 2366609 A DE2366609 A DE 2366609A DE 2366609 C2 DE2366609 C2 DE 2366609C2
- Authority
- DE
- Germany
- Prior art keywords
- capa
- antigen
- gel
- buffer
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000012936 correction and preventive action Methods 0.000 claims description 36
- 239000000427 antigen Substances 0.000 claims description 32
- 102000036639 antigens Human genes 0.000 claims description 32
- 108091007433 antigens Proteins 0.000 claims description 32
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 235000019253 formic acid Nutrition 0.000 claims description 10
- 239000000839 emulsion Substances 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 25
- 239000000499 gel Substances 0.000 description 21
- 239000000843 powder Substances 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000001556 precipitation Methods 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 229920002401 polyacrylamide Polymers 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000007935 neutral effect Effects 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000000284 extract Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 239000013049 sediment Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000002808 molecular sieve Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical compound C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 230000035931 haemagglutination Effects 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical compound NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000237074 Centris Species 0.000 description 1
- 241000698776 Duma Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 229940035422 diphenylamine Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- -1 ether lipid Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000008256 whipped cream Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27027372A | 1972-07-10 | 1972-07-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2366609C2 true DE2366609C2 (no) | 1988-02-25 |
Family
ID=23030635
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2366609A Expired DE2366609C2 (no) | 1972-07-10 | 1973-07-03 | |
| DE19732333740 Granted DE2333740A1 (de) | 1972-07-10 | 1973-07-03 | Antigen, verfahren zu dessen isolierung, bestimmung und dessen verwendung |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19732333740 Granted DE2333740A1 (de) | 1972-07-10 | 1973-07-03 | Antigen, verfahren zu dessen isolierung, bestimmung und dessen verwendung |
Country Status (22)
| Country | Link |
|---|---|
| JP (2) | JPS5817168B2 (no) |
| AR (1) | AR197243A1 (no) |
| AT (1) | AT336780B (no) |
| BE (1) | BE802126A (no) |
| BR (1) | BR7305142D0 (no) |
| CA (1) | CA1039650A (no) |
| CH (1) | CH617853A5 (no) |
| DD (2) | DD113918A5 (no) |
| DE (2) | DE2366609C2 (no) |
| DK (1) | DK139898B (no) |
| ES (1) | ES416726A1 (no) |
| FI (1) | FI60567C (no) |
| FR (1) | FR2191885B1 (no) |
| GB (2) | GB1443053A (no) |
| IL (1) | IL42594A (no) |
| IN (1) | IN138903B (no) |
| IT (1) | IT1009527B (no) |
| NL (1) | NL7309257A (no) |
| NO (1) | NO146338C (no) |
| SE (3) | SE440697B (no) |
| SU (1) | SU581842A3 (no) |
| ZA (1) | ZA734632B (no) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2840039A1 (de) * | 1978-04-28 | 1979-11-08 | Wistar Inst | Verfahren zur erzeugung von tumor- antikoerpern |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4132769A (en) * | 1974-10-30 | 1979-01-02 | Osther Kurt B | Cancer antigen, cancer therapy, and cancer diagnosis |
| US4146603A (en) * | 1977-02-18 | 1979-03-27 | Research Corporation | Tumor specific glycoproteins and method for detecting tumorigenic cancers |
| JPS56145297A (en) * | 1980-04-11 | 1981-11-11 | Kureha Chem Ind Co Ltd | Preparative method of glycoprotein having immunosupressing activity |
| EP0087898A1 (en) * | 1982-02-22 | 1983-09-07 | Cancer Research Campaign Technology Limited | Antibodies and antigens useful in the diagnosis and treatment of cancer |
-
1973
- 1973-06-25 SE SE7308917A patent/SE440697B/xx unknown
- 1973-06-25 IL IL42594A patent/IL42594A/en unknown
- 1973-06-25 IN IN1473/CAL/73A patent/IN138903B/en unknown
- 1973-06-29 FI FI2099/73A patent/FI60567C/fi active
- 1973-07-03 DE DE2366609A patent/DE2366609C2/de not_active Expired
- 1973-07-03 NL NL7309257A patent/NL7309257A/xx not_active Application Discontinuation
- 1973-07-03 DE DE19732333740 patent/DE2333740A1/de active Granted
- 1973-07-06 DD DD172110A patent/DD113918A5/xx unknown
- 1973-07-06 DD DD186676*A patent/DD118946A5/xx unknown
- 1973-07-06 AR AR248979A patent/AR197243A1/es active
- 1973-07-06 CH CH988073A patent/CH617853A5/de not_active IP Right Cessation
- 1973-07-09 GB GB3263473A patent/GB1443053A/en not_active Expired
- 1973-07-09 DK DK380773AA patent/DK139898B/da not_active IP Right Cessation
- 1973-07-09 AT AT600773A patent/AT336780B/de not_active IP Right Cessation
- 1973-07-09 GB GB4980974A patent/GB1443054A/en not_active Expired
- 1973-07-09 IT IT26346/73A patent/IT1009527B/it active
- 1973-07-09 NO NO2807/73A patent/NO146338C/no unknown
- 1973-07-09 ES ES416726A patent/ES416726A1/es not_active Expired
- 1973-07-09 CA CA175,995A patent/CA1039650A/en not_active Expired
- 1973-07-10 FR FR7325241A patent/FR2191885B1/fr not_active Expired
- 1973-07-10 BE BE133300A patent/BE802126A/xx not_active IP Right Cessation
- 1973-07-10 BR BR5142/73A patent/BR7305142D0/pt unknown
- 1973-07-10 SU SU7301949792A patent/SU581842A3/ru active
- 1973-07-10 ZA ZA734632A patent/ZA734632B/xx unknown
- 1973-07-10 JP JP48077839A patent/JPS5817168B2/ja not_active Expired
-
1976
- 1976-09-06 SE SE7609836A patent/SE418186B/xx not_active IP Right Cessation
- 1976-09-06 SE SE7609837A patent/SE440597B/xx not_active IP Right Cessation
-
1981
- 1981-01-14 JP JP56003331A patent/JPS6018011B2/ja not_active Expired
Non-Patent Citations (3)
| Title |
|---|
| Int. Arch. Allergy 36, 191-194, 1968 * |
| J. Exp. Med. 121, 439-441, 1965 * |
| KABAT, E.A.: Einführung in die Immunchemie und Immunologie, S.28-29, Springer-Verlag 1971 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2840039A1 (de) * | 1978-04-28 | 1979-11-08 | Wistar Inst | Verfahren zur erzeugung von tumor- antikoerpern |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2029499C3 (de) | Verfahren zum Nachweis der Anwesenheit von carcinoembryonalen Antigenen im Blut | |
| CH634334A5 (de) | Neues glycoprotein und verfahren zu dessen herstellung. | |
| DE2127159C2 (de) | IgG-Immunglobulinfraktion und ihre Herstellung | |
| EP0009715B1 (de) | Neues ubiquitäres Gewebsprotein PP8 und Verfahren zu seiner Anreicherung | |
| DE2640387C3 (de) | Gewebespezifisches Protein und Verfahren zu dessen Herstellung | |
| EP0101063B1 (de) | Neues Polypeptid mit Wirkung auf das Immunsystem, Verfahren zu seiner Isolierung und Reinigung, seine Verwendung und dieses enthaltende Mittel | |
| DE2366609C2 (no) | ||
| EP0060491A2 (de) | Protein (PP16), Verfahren zu seiner Anreicherung und Gewinnung sowie seine Verwendung | |
| DE69110060T2 (de) | In der humantherapie nützliche substanzen peptidischer natur. | |
| DE68911693T2 (de) | Pharmazeutisches mittel für behandlung von menschlichem krebs und verfahren zu seiner herstellung. | |
| WO1997034929A1 (de) | Verfahren zur gewinnung eines komplexes aus wachstumsfaktoren | |
| DE1767899A1 (de) | Verfahren zur Isolierung von Antigenen und Antikoerpern | |
| CH659586A5 (de) | Arzneimittel aus dem thymus und verfahren zu dessen herstellung. | |
| DE2234832C2 (de) | Proteinfreies Hormonkonzentrat von Säugetier-Nebenschilddrüsen, dessen Herstellung und dieses Hormonkonzentrat enthaltende pharmazeutische Präparate | |
| DE3306944A1 (de) | Fibrinolytisch aktives mittel und verfahren zu seiner herstellung | |
| DE1617332C3 (de) | Verfahren zum Isolieren eines wasserlöslichen Protein-Metall-Chelats mit antiphlogistischer Wirkung | |
| CH634854A5 (de) | Verfahren zur herstellung organopeptidhaltiger substanzen mit insulinaehnlicher wirksamkeit aus blut oder blutbestandteilen. | |
| EP0107782A1 (de) | Verfahren zur Isolierung von Relaxin | |
| DE2815758C3 (de) | Peptidkomplexe aus DNS-haltigen Organismen | |
| Bauer | Studies on Isolated Keratin Fractions from Mammalian Epidermis: I. Physicochemical Properties of the Fractions | |
| DE1767099B1 (de) | Verfahren zur Gewinnung eines Glykoproteins mit einer Hemmwirkung gegenueber Magensaeureabsonderung und einer Antiaktivitaet gegenueber Ulcus-Bildung | |
| DE2062558A1 (de) | Mittel zur Diagnose von primärem Leberkrebs und Verfahren zur Her stellung desselben | |
| EP0396597A1 (de) | Verfahren zur herstellung eines therapeutisch aktiven, insbesondere zur wundheilung oder zur behandlung in der geriatrie verwendbaren wirkstoffes und ein einen solchen wirkstoff enthaltendes therapeutisches präparat | |
| JPS61200923A (ja) | 抗アレルギ−作用を有する物質とその製造方法 | |
| DE1767099C (de) | Verfahren zur Gewinnung eines Glykoproteins mit einer Hemmwirkung gegenüber Magensäureabsonderung und einer Antiaktivität gegenüber Ulcus-Bildung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| Q172 | Divided out of (supplement): |
Ref country code: DE Ref document number: 2333740 |
|
| 8110 | Request for examination paragraph 44 | ||
| 8181 | Inventor (new situation) |
Free format text: BJOERKLUND, KNUT BERTIL, DR.MED., BROMMA, SE |
|
| AC | Divided out of |
Ref country code: DE Ref document number: 2333740 Format of ref document f/p: P |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition |